Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dapagliflozin/Metformin XR from Two Manufacturing Plants
NCT03216278Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Sep 2017; status: completed.
02
Drugs
dapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03216278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216278.